Tivic shareholders approve key proposals in support of strategic transformation; lisa wolf appointed permanent cfo

Fremont, calif.--(business wire)--tivic health® systems, inc. (nasdaq: tivc), a diversified immunotherapeutics company, today announced that key proposals needed to carry out the company's strategic transformation were approved by shareholders at its annual meeting held on june 30, 2025. the approved proposals included the issuance of equity as a form of payment pursuant to tivic's worldwide exclusive license agreement for entolimod™ and entolasta™, including for uses in acute radiation syndrom.
TIVC Ratings Summary
TIVC Quant Ranking